MNCs Eye Generics Buys To Enter Growing Southeast Asia Markets

Making generic pharmaceuticals have become a major tool for foreign drug makers to get access to emerging markets in Southeast Asia as those markets outstrip the developed world in growth rates. Many multinationals are seeing their chances of growth more limited in developed markets, so they look to generics as a way to diversify. Emerging markets are expected to grow three times as fast as Western markets, by 13 percent a year, and account for 40 percent of the global drug market by 2020. The proposed acquisition of India's Ranbaxy Laboratories by Japan's Daiichi-Sankyo is cited by analysts as indicative of interest in the developing world. (Click here for more